Because tumor cells that lost MSH6 generally exhibit high mutation rates in many genes and high levels of microsatellite instability, minority portions of this patient’s tumor could be a mixture of EMAST plus MSI-H and in theory could benefit treatment with combined use of some types of chemotherapy12 and immune checkpoint inhibitors13 for which was tried as therapy for this patient. The gene discussed is MSH6; the disease is neoplasm.